De Luca Fabrizio, Losappio Laura Michelina, Mirone Corrado, Schroeder Jan Walter, Citterio Antonella, Aversano Maria Gloria, Scibilia Joseph, Pastorello Elide Anna
Department of Allergology and Immunology, Ospedale Metropolitano Niguarda Ca' Granda, Piazza Ospedale Maggiore, 3, 20162 Milan, Italy.
Department of Burn/Intensive Care, Ospedale Metropolitano Niguarda Ca' Granda, Milan, Italy.
Clin Mol Allergy. 2017 Oct 4;15:16. doi: 10.1186/s12948-017-0072-5. eCollection 2017.
Anticonvulsant hypersensitivity syndrome represents a rare but potentially fatal kind of adverse drug reaction. This clinical picture often hampers the flexibility with which alternative anticonvulsants or even other classes of drugs are prescribed in these patients, negatively affecting the efficacy of treatment and the course of the disease. The aim of this study was to analyse a group of six patients with severe cutaneous drug reactions induced by anticonvulsants and to report which alternative antiepileptic drugs and which drugs of other classes were tolerated.
A total of six patients (2 males and 4 females, age 11-73 years) are described in this study. In all the patients the onset of the severe cutaneous drug reactions was 2-4 weeks after initiating the anticonvulsant therapy: 2 out of 6 patients presented with a drug reaction with eosinophilia and systemic symptoms under therapy with phenytoin; 2 out of 6 presented with Stevens-Johnson syndrome under therapy with lamotrigine; and 2 out of 6 presented with a toxic epidermal necrolysis, one of them under therapy with valproic acid, and the other one under therapy with lamotrigine. Alternative anticonvulsants tolerated after the reaction were: clonazepam, levetiracetam, diazepam, delorazepam and lormetazepam.
In our cases we observed that non aromatic anticonvulsants and benzodiazepines were well tolerated as alternative treatments in six patients with reactions to aromatic anticonvulsivants and that the risk of hypersensitivity reactions to other drug classes was not increased as compared to general population.
抗惊厥药超敏反应综合征是一种罕见但可能致命的药物不良反应。这种临床表现常常限制了为这些患者开具替代抗惊厥药甚至其他类药物的灵活性,对治疗效果和病程产生负面影响。本研究的目的是分析一组6例由抗惊厥药引起严重皮肤药物反应的患者,并报告哪些替代抗癫痫药物以及其他类别的哪些药物是可耐受的。
本研究共描述了6例患者(2例男性,4例女性,年龄11 - 73岁)。所有患者在开始抗惊厥治疗后2 - 4周出现严重皮肤药物反应:6例患者中有2例在苯妥英治疗期间出现伴有嗜酸性粒细胞增多和全身症状的药物反应;6例中有2例在拉莫三嗪治疗期间出现史蒂文斯 - 约翰逊综合征;6例中有2例出现中毒性表皮坏死松解症,其中1例在丙戊酸治疗期间出现,另1例在拉莫三嗪治疗期间出现。反应后可耐受的替代抗惊厥药有:氯硝西泮、左乙拉西坦、地西泮、去氯羟嗪和氯美扎酮。
在我们的病例中,我们观察到对于6例对芳香族抗惊厥药有反应的患者,非芳香族抗惊厥药和苯二氮䓬类药物作为替代治疗耐受性良好,并且与普通人群相比,对其他药物类别的超敏反应风险并未增加。